Brümmendorf, Tim Henrik, Univ.-Prof. Dr. med.   ***08.09.1966 (m)**

Head, Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation
Director, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO^ABCD)
University Hospital RWTH Aachen
Pauwelsstr. 30, D-52074 Aachen
Phone: +49 241 8089806
E-mail: tbruemmendorf@ukaachen.de

Professor (W3) of Oncology and Hematology, Married, 3 Children

1.   Scientific and Clinical Training

2007	European School of Medical Oncology (ESMO) Exam
2005	Board exam in Hematology and Medical Oncology
2003	Board exam in Internal Medicine
1997-1999	Post-doctoral Research Fellowship (DFG), Vancouver, Canada
1995-97,1999-03	Clinical Residency in Internal Medicine, University of Tübingen
1988-1995	Medical School, Ruprecht-Karl-University, Heidelberg, Germany

2.   Academic Degrees

2009	Full W3-Professor of Medicine, RWTH Aachen University
2007	Professor of Medicine, University of Hamburg
2004	Venia legendi (Priv.-Doz.), University of Tübingen
1995	M.D. thesis, University of Heidelberg (*summa cum laude*)

3.   Academic Appointments

Since 2022	Spokesperson, Board of directors, CIO Aachen-Bonn-Cologne-Düsseldorf (CIO^ABCD)
Since 2019	Speaker, Klinische Forschungsgruppe der DFG (CRU344)
2016-2021	Vice-Dean, Structural/Financial Affairs, Med. Faculty, RWTH Aachen
Since 2015	Co-Founder/co-speaker, German Study Group MPN (GSG-MPN)
Since 2010	Founder and Head, Center for Integrated Oncology-Aachen (CIO^A)
Since 2009	Head, Dept. of Oncology, Hematology and Stem Cell Transplantation, University Hospital RWTH Aachen
2007-2009	Deputy Head, Dept. of Hematology/Oncology, University Hospital and University Cancer Center (UCCH), Hamburg-Eppendorf

4. Honors, awards and professional activities

Honours and Awards (selection): Science Award, Interdisciplinary group of lab research/flow cytometry (IGLD) 2006; Artur Pappenheim Award, German Society of Hematology/Oncology (DGHO) 2000

Professional activities (selection): since 2015: Nachwuchsausschuß Deutsche Krebshilfe (DKH), since 2020: Wissenschaftlicher Beirat der DKH; since 2019: Lenkungsausschuss der Onkologischen Spitzenzentren der DKH; since 2019: Steering committee, Exploratory research space (ERS) of the Excellence Initiative, RWTH Aachen; 2019-2021: Speaker, Verein der Universitären Hämatologen und Onkologen (VUHO); since 2018: Member of the Strategy Board, European School of Hematology (ESH)

5. Selected publications

1. **Brümmendorf TH**, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, Garcia-Gutierrez V, Chuah C, Kota V, Lipton JH, Rousselot P, Mauro MJ, Hochhaus A, Hurtado Monroy R, Leip E, Purcell S, Yver A, Viqueira A, Deininger MW; BFORE study investigators. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022 May 28. doi: 10.1038/s41375-022-01589-y.
2. Leimkühler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, Kuppe C, Stalmann USA, Büsche G, Kreipe H, Gütgemann I, Krebs P, Banz Y, Boor P, Tai EW, **Brümmendorf TH**, Koschmieder S, Crysandt M, Bindels E, Kramann R, Costa IG, Schneider RK. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2021; 28(4):637-652
3. Cortes JE, Gambacorti-Passerini C, Deininger M, Mauro M, Chuah C., Kim D-W, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, **Brümmendorf TH** Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial J. Clin Oncol 2018; 36(3):231-237
4. Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, Beier F, **Brümmendorf TH**, Germing U, Platzbecker U, Büsche G, Knüchel R, Chen MC, Waters CS, Chen E, Chu LP, Novina CD, Lindsley RC, Carr SA, Ebert BL. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med. 2016; 22(3):288-97
5. Braig M, Pallmann N, Preukschas M, Steinemann D, Hofmann W, Gompf A, Streichert T, Braunschweig T, Copland M, Rudolph KL, Bokemeyer C, Koschmieder S, Schuppert A, Balabanov S, **Brümmendorf TH**. A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. Leukemia 2014, 28(10):2028-2039.
6. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, **Brümmendorf TH**. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012, 119(15):3403-3412.
7. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, **Brümmendorf TH.** Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008; 111(8):4355-4364.
8. Balabanov S, Gontarewicz A, Ziegler P, Hartmann U, Kammer W, Copland M, Brassat U, Priemer M, Hauber I, Wilhelm T, Schwarz G, Kanz L, Bokemeyer C, Hauber J, Holyoake TL, Nordheim A, **Brümmendorf TH**. Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 2007, 109(4):1701-1711.
9. **Brümmendorf TH,** Holyoake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ, Eaves AC, Lansdorp PM. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000, 95(6):1883-1890.
10. Rufer N*, **Brümmendorf TH***, Kolvraa S, Bischoff C, Christensen K, Wadsworth L, Schulzer M, Lansdorp PM. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 1999; 190(2):157-167. *equal contribution